John Carroll

"anger, anxiety, frustration, and fear" -- you know you're in a world of hurt when any description of Wall Street's mood does not include the word greed. https://t.co/Q2gyThS8dG

What comes from #voodoohealthcare, courtesy @RFKJr_Official and @realDonaldTrump. Lots more ahead. https://t.co/ldEKqRfLSR

A lot of people had an incredibly bad week, so you just can't moan about the state of biopharma. But a quack runs HHS, the FDA is in chaos, financial markets are shell shocked -- the XBI down 20% YTD -- as President Orange Dumbass is single handedly reversing 80 years of

Thanks, Mike. I had a lot of fun. Instead of my usual panels, I went one-on-one with Mike Rea @ideapharma to learn more about innovation and talk about the latest trends in biopharma. I think it's well worth the time to listen in and let me know what you think. (Really, I'm

Mike Rea, IDEA Pharma @ideapharma

My talk with @JohnCendpts of @endpts News on this year's R&D15 was stimulating - we covered so much, which is easy, given John's range across all of what matters... You can see the interview here - I don't think I said anything I shouldn't have, this year! https://t.co/Vg9pe7VYJ2

RT @AmberTongPW: Novo Holdings Wants to Do More China Biotech Deals, CEO Says https://t.co/myLxjN9d7l via @business

Big Pharma is not going to line up in public against gutting the FDA or anything else happening in the Trump admin. Right now the only response suitable to Trump is: 'Please, sir, may I have another.' They want to escape the worst pain, and they will do and say virtually anything

As markets slide on the DUMB Trump tariff taxes, @ky_lahucik looks at the plunge in $$ going through the PIPE to biotech in Q1. This will make it much harder for biotechs to weather the downturn. Looking kind of bleak out there at the start of Q2. Businesses had been looking for

DAY #252 from the initial cancer blast. In for my regular infusion of avelumab at MD Anderson. If there's a routine in cancer treatment, I'm on it. PD-L1 keeps the Merkel cell carcinoma army at bay, for now, still in the "so far so good" stage of falling off the building. You get

Arie Belldegrun keeps on truckin' at Vida; 4th fund underway. @ky_lahucik has the story/with the context https://t.co/SUeJUfGNZy

RT @ideapharma: @barttels2 @JohnCendpts Ha! That’s interesting - I’d not noticed the tone of my tweets trending less cheery! I think India…

When incompetence turns creepy: "Some federal health employees who were laid off Tuesday were told to contact Anita Pinder, who died last year, with discrimination complaints." https://t.co/ZzJHHQNno0

RT @ScottGottliebMD: 🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely e…

Tune in to my conversation with @ideapharma at noon ET as we discuss the R&D 15 and research strategies among the biggest spenders in biopharma. The numbers keep getting bigger. https://t.co/XSDHwXrKaB

RT @ky_lahucik: Former FDA commissioner Rob Califf, who led the regulator under Obama and Biden administrations, said in a LinkedIn post th…

OK, back to regular programming as chaos reigns at the FDA. I hope you weren't planning to talk to regulators about, you know, new drugs or anything. @ZacharyBrennan covers the destruction of the agency. https://t.co/L6XQp1k73C

If I could get your attention for a moment while the FDA burns, here's the R&D 15, the biggest research spenders in the industry. (Maybe earmark it for a quieter time) https://t.co/USxEvCAvtn

RT @SarahKarlin: SCOOP: New FDA commissioner Martin Makary was sworn in Friday before HHS tried to push Peter Marks out, knew it was going…